BA
Baroda BNP Paribas Health and Wellness Fund Direct Growth
Latest NAV
+11.88% 1Y
Sign In to Add to Portfolio
Benchmark: BSE Healthcare TRI
Expense ratio
1.04%
AUM
₹507 Cr
Min SIP
₹500
Min lump sum
₹1,000
1Y
+11.88%
3Y (ann.)
+0.00%
5Y (ann.)
+0.00%
Launched
Jun 2025
Where the NAV sits & how risky it is
₹10.57
52-week range
at 72%
₹10.57
Low 29 Jan 2026₹9.06
High 23 Sep 2026₹11.15
Risk level
Very High
Low
Very high
NAV history
01 Jul 2025
Since inception
05 Oct 2026
Returns by period
1W
-3.30%
1M
-2.94%
3M
+2.62%
6M
+16.27%
1Y
+11.88%
3Y
+0.00%
5Y
+0.00%
3Y and 5Y returns are annualised.
Return calculator
You invest
—
Est. gain
—
Est. value
—
Invested Gain
Invested
Projected value
min SIP ₹500
Estimate only. It assumes the selected past return repeats every year; 3Y and 5Y figures are taken as annualised. Actual returns vary and are not guaranteed.
Where your money goes
AS OF 31 MAY 2026
Equity 97.41%
Cash & other 4.72%
Sector split
Country split
Top 5 hold 31.4%
Top 10 hold 54.0%
36 equity holdings
Equity holdings
(top 30)
| # | Holding | Sector | Country | Weight | YTD |
|---|---|---|---|---|---|
| 1 | Sun Pharmaceutical
INE044A01036 |
Healthcare Drug Manufacturers - Specialty & Generic |
India |
9.09%
|
+8.96% |
| 2 | Lupin
INE326A01037 |
Healthcare Drug Manufacturers - Specialty & Generic |
India |
5.83%
|
+11.09% |
| 3 | Laurus Labs
INE947Q01028 |
Healthcare Drug Manufacturers - Specialty & Generic |
India |
5.76%
|
+30.97% |
| 4 | Abbott
INE358A01014 |
Healthcare Drug Manufacturers - Specialty & Generic |
India |
5.43%
|
-11.85% |
| 5 | Torrent Pharmaceuticals
INE685A01028 |
Healthcare Drug Manufacturers - Specialty & Generic |
India |
5.27%
|
+18.29% |
| 6 | IPCA Laboratories
INE571A01038 |
Healthcare Drug Manufacturers - Specialty & Generic |
India |
5.18%
|
+14.05% |
| 7 | Apollo Hospitals
INE437A01024 |
Healthcare Medical Care Facilities |
India |
4.66%
|
+22.14% |
| 8 | J B Chemicals and Pharmaceuticals
INE572A01036 |
Healthcare Drug Manufacturers - Specialty & Generic |
India |
4.38%
|
+24.52% |
| 9 | Fortis Healthcare
INE061F01013 |
Healthcare Medical Care Facilities |
India |
4.27%
|
+8.01% |
| 10 | AstraZeneca Pharma
INE203A01020 |
Healthcare Drug Manufacturers - Specialty & Generic |
India |
4.12%
|
-7.07% |
About this scheme
The primary objective of the Scheme is to provide long-term capital appreciation by investing predominantly in equity and equity related instruments of Pharma and Healthcare companies. The Scheme does not guarantee/indicate any returns. However, there can be no assurance that the investment objective of the Scheme will be realized.
Fund manager(s): Rohan Korde, Ankeet Pandya
Exit load: Exit Load for units in excess of 10% of the investment,1% will be charged for redemption within 1 year.
Scheme snapshot
VR Rating
MS Rating
Plan
Growth
Type
DIRECT
Inception
27 Jun 2025
Lump-sum min
₹1,000
SIP
Purchase
Switch
STP
SWP
Similar schemes
RANKED BY 1Y RETURN
Nippon India Taiwan Equity Fund Direct Growth
1▲ 109.7 pts ahead of this fund
Franklin Asian Equity Fund Direct Growth
2▲ 21.5 pts ahead of this fund
Nippon India Japan Equity Fund - Direct Plan - Growth Plan - Bonus Option
3▲ 18.7 pts ahead of this fund
Nippon India Japan Equity Fund Direct Growth
4▲ 18.7 pts ahead of this fund
Bank of India Small Cap Fund Direct Growth
5▲ 17.4 pts ahead of this fund
TRUSTMF Small Cap Fund Direct Growth
6▲ 17.3 pts ahead of this fund